A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Yongchang Zhang186 enrolled

Overview

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

Study Type

OBSERVATIONAL

Enrollment

186

Conditions

Non Small Cell Lung Cancer

Interventions

immunity therapyDRUG

The patient receives immunotherapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1.Diagnosed as advanced non-small cell lung cancer * 2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation Exclusion Criteria: * The patient is diagnosed with small cell lung cancer

Locations (2)

Hunan Cancer Hospital

Changsha, Hunan, China

RECRUITING

Hunan Cancer hospital

Changsha, Hunan, China

RECRUITING

Outcomes

Primary Outcomes

PFS

Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Time frame: January 2021- January 2021 (1 year)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.